FindMyKOL
Clinical trialNCT03953898Active, not recruitingPhase 2Interventional

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

SponsorNational Cancer Institute (NCI)Enrollment14Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well olaparib works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or myelodysplastic syndrome. Patients must also have a change in the gene called the IDH gene (IDH mutation). Olaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc Irvine Health/chao Family Comprehensive Cancer Center

    Orange, California, United States

  • Yale University

    New Haven, Connecticut, United States

  • Um Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida, United States

  • Um Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, United States

  • Um Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida, United States

  • University of Maryland/greenebaum Cancer Center

    Baltimore, Maryland, United States

  • Dartmouth Hitchcock Medical Center/dartmouth Cancer Center

    Lebanon, New Hampshire, United States

  • Wake Forest University at Clemmons

    Clemmons, North Carolina, United States

  • Wake Forest Baptist Health - Wilkes Medical Center

    Wilkesboro, North Carolina, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Olaparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Aug 2020
Primary completion
16 Jan 2024
Completion
4 Mar 2027
Last update posted
1 Jun 2026
Registered enrollment
14
Registry id
NCT03953898
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.